FDA “Broad Agency Announcement” To Fund Generic, Clinical Design Research
Agency expects to provide $200,000 to $50 million on a wide range of research proposals to support regulatory science and innovation.
You may also be interested in...
GPhA recommends FDA deploy user fee research money to look at shortage risk assessment and mitigation strategies, while the trade group continues to look for a product to fit its own shortage prediction model.
FDA Commissioner takes a softer tone in repeating the message that quality must improve in the generics industry, saying the reward may manifest in inspection policy.
Agency’s recent approval of Enhertu, which has better response rate, sways some panel members to vote against Spectrum’s NSCLC drug. FDA’s Pazdur compares poziotinib’s dosing uncertainty to ‘building a house on quicksand.’